Altimmune Stock Price, News & Analysis

Altimmune has reported promising results from a Phase 1 trial of its investigational drug, pemvidutide, intended for obesity and NASH treatment. Subjects receiving the 1.8 mg dose achieved a mean weight loss of 10.3% over 12 weeks, with no treatment discontinuations due to adverse events. The drug was well-tolerated, and the IND for NASH has cleared FDA review. Future clinical studies, including a 12-week NAFLD trial, are set to commence soon. Altimmune plans to initiate a 48-week Phase 2 obesity trial in H1 2022.

Altimmune, Inc. (Nasdaq: ALT) announced the upcoming results of its 12-week Phase 1 clinical trial for ALT-801, aimed at treating obesity, to be released on September 28, 2021. The company will provide details during a conference call and webcast at 8:30 AM ET, which will also be available for replay on its website. This trial represents a significant step in Altimmune's development pipeline focused on obesity and liver diseases, part of its broader strategy to advance next-generation therapeutics.

Altimmune, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be led by CEO Vipin Garg and CMO Scott Harris, with a pre-recorded session available on September 13 at 7 a.m. EST. Altimmune focuses on developing treatments for obesity and liver diseases, including therapies like ALT-801 for NASH and HepTcell™ for chronic hepatitis B. For further details, visit Altimmune's website.

Altimmune, Inc. (Nasdaq: ALT) has announced its financial results for Q2 2021, reporting a cash position of approximately $218 million, enabling ongoing development of its obesity and liver disease pipeline. The interim results from the ALT-801 Phase 1 trial showed a placebo-adjusted weight loss of 6.3% over six weeks. The 12-week data readout for ALT-801 is expected in September 2021, alongside plans for IND applications in NASH and obesity. Revenue was $0.1 million, down from $0.7 million YoY, with a net loss of $24.8 million for the quarter.

Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2021 financial results on August 11, 2021. Management will host a conference call at 8:30 am E.T. to discuss the results and provide further business updates. The conference can be accessed via dial-in or webcast. Altimmune is focused on developing treatments for obesity and liver diseases, with a pipeline that includes therapies for NASH and chronic hepatitis B.

Altimmune (Nasdaq: ALT) has announced the discontinuation of its AdCOVID vaccine development after a Phase 1 trial revealed it was well tolerated but failed to generate adequate immune responses compared to existing COVID-19 vaccines. The focus will shift to advancing its obesity and liver disease programs, notably ALT-801 and HepTcell. Encouraging interim data from the ALT-801 trial indicate significant weight loss in overweight participants. Meanwhile, enrollment challenges in the T-COVID Phase 1/2 trial have led to the decision to halt further enrollment while evaluating future development options.

Altimmune announced interim results from its Phase 1 trial of ALT-801, a dual GLP-1/glucagon receptor agonist, showing a significant 5.4% weight loss at 6 weeks with a 1.8 mg dose, exceeding the 2% target. The treatment was well-tolerated with low nausea rates. Further developments include plans to file an additional IND for an obesity program in 2021 and an anticipated 12-week data readout in Q3 2021. The trial aims to explore ALT-801's effects on liver fat and metabolic conditions, enhancing its therapeutic potential in tackling obesity and NASH.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, will participate in the 2021 Jefferies Virtual Healthcare Conference from June 1 to 4, 2021. The management team, including Vipin Garg, Scot Roberts, and Scott Harris, will present on June 2, 2021 at 11:30 am ET. Attendees can access the presentation through a webcast link on the Altimmune website. Altimmune focuses on developing intranasal vaccines and therapies for various diseases, including its COVID-19 vaccine, AdCOVID™.

Altimmune reported promising preclinical results for its AdCOVID vaccine against the South African variant B.1.351. The neutralizing titers against this variant were only 4.4-fold lower than those against the original SARS-CoV-2 strain after a single intranasal dose. A booster dose further narrowed this gap to 1.8-fold. The study also highlighted strong mucosal immunity, suggesting that AdCOVID could effectively combat variants while simplifying vaccination strategies. The company aims to report Phase 1 trial data in June 2021, with a focus on its potential to provide broad immune responses.